Paper - WANFANG MED ONLINE

You Position: Home > Paper

Role of gut-liver axis dysfunction in pathogenesis of non-alcoholic fatty liver disease: Implications for treatment strategies

( views:22, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 24

DOI:: 10.11569/wcjd.v26.i24.1439

Key Word:: 肠-肝轴;非酒精性脂肪肝病;肠道屏障;肠道微生物

Abstract：众所周知,非酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)作为一个慢性代谢性疾病,其发病机制复杂,涉及到诸多因素.其中肠道微生物失衡所导致的机体代谢紊乱是NAFLD发生发展的一个重要诱因.相关研究发现肠道菌群的失调可引起肠道屏障的破坏,进而导致相关有毒代谢产物入血和细菌移位的发生,诱发肝脏炎症反应和损伤.在此过程中,肠肝之间的“对话”体现了肠-肝轴在NAFLD/NASH发病过程中的重要地位.因此,本文将就肠-肝轴参与NAFLD的发病机制及相关潜在的治疗策略进行一个简要的评述.

Reference

[1]王峻瑶,刘玉兰.肠-肝轴在非酒精性脂肪性肝病发生和发展中的作用[J].2012,(4).
[2]南月敏,付娜,李文聪,等.2017美国非酒精性脂肪性肝病诊断与管理指南解读[J].2017,(9).
[3].肝脏与固有免疫研究进展[J].2009,(5).
[4]周达,范建高.肠道菌群-SCFAs在代谢性疾病中的作用研究[J].2016,(3).
[5]宋丹丹,刘煜.肠道菌群变化在2型糖尿病诊疗中的价值[J].2017,(1).
[6]刘玉兰,胡莹."肠-肝轴"带给我们的启示[J].2011,(5).
[7]Bajaj Jasmohan S.,Kakiyama Genta,Zhao Derrick,etc.Continued Alcohol Misuse in Human Cirrhosis is Associated with an Impaired Gut–Liver Axis[J].2017,41(11).
[8].Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis.[J].2010,5(3).
[9]何剑,阳学风.肠道菌群与非酒精性脂肪性肝病[J].2017,(27).
[10]Pietro, Vajro,Claudia, Mandato,Claudio, Veropalumbo,etc.Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease.[J].1900,12(1).
[11]Smits,L.P.,Bouter,K.E.C.,DeVos,W.M.,etc.Therapeutic potential of fecal microbiota transplantation[J].2013,145(5).
[12]Jennifer Y, Kasper,Maria Iris, Hermanns,Christian, Cavelius,etc.The role of the intestinal microvasculature in inflammatory bowel disease: studies with a modified Caco-2 model including endothelial cells resembling the intestinal barrier in vitro.[J].1900,11.
[13]Gijs, den Besten,Aycha, Bleeker,Albert, Gerding,etc.Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation.[J].2015,64(7).
[14]Bliss SK,Bliss SP,Beiting DP,etc.IL-10 regulates movement of intestinally derived CD4+ T cells to the liver.[J].2007,178(12).
[15]Wigg A J.The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis[J].2001.
[16]王璐璇,刘玥宏,朱继开,等.短链脂肪酸在疾病治疗中的研究进展[J].2017,(13).
[17]Rooks, Michelle G.,Garrett, Wendy S..Gut microbiota, metabolites and host immunity[J].2016,16(6).
[18]D Peter, O'Leary,Lavinia, Bhatt,John F, Woolley,etc.TLR-4 signalling accelerates colon cancer cell adhesion via NF-κB mediated transcriptional up-regulation of Nox-1.[J].2012,7(10).
[19]Kim, Seungbum,Goel, Ruby,Kumar, Ashok,etc.Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure.[J].2018,132(6).
[20]Silvia M, Ferolla,Geyza N A, Armiliato,Cláudia A, Couto,etc.The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.[J].2014,6(12).
[21]Sato, F. T,Sampaio, S. C,Curi, R.,etc.Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils.[J].2011,22(9).
[22]Li, Xue,Juntao, He,Ning, Gao,etc.Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.[J].2017,7(Spec ).
[23]Ze-Xuan, Wu,Su-Fang, Li,Hong, Chen,etc.The changes of gut microbiota after acute myocardial infarction in rats.[J].2017,12(7).
[24]沈定树,郑静.益生元与肠道微生态[J].2013,(6).
[25]Marco, Poeta,Luca, Pierri,Pietro, Vajro.Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.[J].2017,4(8).
[26]Niu, Rong,Li, Wenxia,Zeng, Benhua,etc.The Development and Stability of the Genus Bacteriodes from Human Gut Microbiota in HFA Mice Model[J].2011,62(4).
[27]Day CP,de-Alwis NM.Non-alcoholic fatty liver disease: the mist gradually clears.[J].2008,48(Suppl.1).
[28]Isabel Gómez-Hurtado,José Such,Yolanda Sanz,etc.Gut microbiota-related complications in cirrhosis[J].2014,(42).
[29]Li JL,Pircher PC,Westin SK,etc.Regulation of complement C3 expression by the bile acid receptor FXR[J].2005,280(9).
[30]Park JS,Kim WK,Lee EJ,etc.Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways.[J].2007,7(1).
[31]Farrell GC,Fan JG.Epidemiology of non-alcoholic fatty liver disease in China.[J].2009,50(1).
[32]Tian ZG,Gao B,Jeong WI.Liver: An organ with predominant innate immunity[J].2008,47(2).
[33]韩德五.肠源性内毒素血症所致"继发性肝损伤"的临床依据[J].1999,(12).
[34]Begley, Máire,Hill, Cohn,Gahan, Cormac G. M..Bile Salt Hydrolase Activity in Probiotics.[J].2006,72(3).
[35]唐外姣,周本杰.肠道菌群失调--非酒精性脂肪肝病治疗新靶点[J].2017,(22).
[36]Jones, Rheinallt M.,Neish, Andrew S..Redox signaling mediated by the gut microbiota[J].2017,105.
[37]JIA XU,ZHIHAO LIU,WEI ZHAN,etc.Recombinant TsP53 modulates intestinal epithelial barrier integrity via upregulation of ZO-1 in LPS-induced septic mice.[J].2018,17(1).
[38]P, Vajro,C, Veropalumbo,R, D'Aniello,etc.Probiotics in the treatment of non alcoholic fatty liver disease: further evidence in obese children.[J].2013,23(1).
[39]Kristina Schoonjans,Bernd Schnabl,Alessia Perino,etc.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J].2015,21(2).
[40]F, Megerlin,E, Fouassier.[Faecal microbiota transplantation in France: what applicable law?].[J].2014,72(5).
[41]Day,CP,James,OF.Steatohepatitis: a tale of two "hits"? (editorial)[J].1998,114(4).
[42]Crane, Rosie J.,Jones, Kelsey D. J.,Berkley, James A..Environmental enteric dysfunction: An overview[J].2015,36(1 Suppl.1).
[43]Christopher D. Byrne,Giovanni Targher.NAFLD: A multisystem disease[J].2015,62(Supplement).
[44]Kumar, Dinesh,Pandey, Gaurav,Bansal, Deepak,etc.NMR-based urinary profiling of lactulose/mannitol ratio used to assess the altered intestinal permeability in acute on chronic liver failure (ACLF) patients[J].2017,55(4).
[45]Jay Luther,John J. Garber,Hamed Khalili,etc.Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability[J].2015,1(2).
[46]Gao, F.,Dai, S. F.,Zhou, G. H.,etc.Sodium butyrate maintains growth performance by regulating the immune response in broiler chickens.[J].2011,52(3).
[47]Garland SH.Short chain fatty acids may elicit an innate immune response from preadipocytes: a potential link between bacterial infection and inflammatory diseases.[J].2011,76(6).
[48]Ma,Y.,Huang,Y.,Yan,L.,etc.Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance[J].2013,30(5).
[49]Kapoor,A.,Mirshahi,F.,Maher,J.,etc.Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease[J].2012,15(5).
[50].Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J].2012,143(4).
[51]Cani PD,Bibiloni R,Knauf C,etc.Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.[J].2008,57(6).
[52]Mir, Hina,Meena, Avtar S.,Chaudhry, Kamaljit K.,etc.Occludin deficiency promotes ethanol-induced disruption of colonic epithelial junctions, gut barrier dysfunction and liver damage in mice[J].2016,1860(4).